



# Advancing narrow-spectrum protein antibiotics for *Enterobacteriaceae*


Broad-spectrum antibiotics can kill good bacteria along with harmful ones, disrupt the body's natural balance and increase the risk of antimicrobial resistance over time



Glox Therapeutics is developing novel narrow-spectrum antibiotics by engineering proteins called bacteriocins to tackle infections caused by multidrug resistant bacteria




Bacteriocins are naturally produced by bacteria to kill specific competitors




Modifying bacteriocins has the potential to create antibiotics active against a narrow range of bacteria

The Glox technology platform generates engineered bacteriocins with different mechanisms that can enter and kill target bacteria



With support and funding from PACE, the team will

- Generate a library of engineered bacteriocins to target gram-negative bacteria
- Identify those with the right properties to be developed into a medicine for lung infections



Success with the project would move Glox Therapeutics further towards their aim of developing a new treatment for hospital-acquired and ventilator acquired pneumonia

Especially infections caused by multidrug resistant *E.coli* and *Klebsiella pneumoniae*

